Barinthus Biotherapeutics (BRNS) Competitors $1.14 +0.04 (+3.45%) Closing price 08/20/2025 03:50 PM EasternExtended Trading$1.12 -0.01 (-1.32%) As of 08/20/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. SXTC, DERM, TVGN, CYBN, ACRS, LFVN, CCCC, VYGR, GLSI, and CTNMShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include China SXT Pharmaceuticals (SXTC), Journey Medical (DERM), Semper Paratus Acquisition (TVGN), Cybin (CYBN), Aclaris Therapeutics (ACRS), Lifevantage (LFVN), C4 Therapeutics (CCCC), Voyager Therapeutics (VYGR), Greenwich LifeSciences (GLSI), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors China SXT Pharmaceuticals Journey Medical Semper Paratus Acquisition Cybin Aclaris Therapeutics Lifevantage C4 Therapeutics Voyager Therapeutics Greenwich LifeSciences Contineum Therapeutics Barinthus Biotherapeutics (NASDAQ:BRNS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Which has higher valuation & earnings, BRNS or SXTC? China SXT Pharmaceuticals has lower revenue, but higher earnings than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M3.07-$61.07M-$1.73-0.66China SXT Pharmaceuticals$1.74M106.36-$3.30MN/AN/A Which has more volatility and risk, BRNS or SXTC? Barinthus Biotherapeutics has a beta of -0.73, meaning that its stock price is 173% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Do insiders and institutionals have more ownership in BRNS or SXTC? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 10.7% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend BRNS or SXTC? Barinthus Biotherapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 163.16%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor BRNS or SXTC? In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.48 beat Barinthus Biotherapeutics' score of 0.27 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Barinthus Biotherapeutics Neutral China SXT Pharmaceuticals Neutral Is BRNS or SXTC more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -54.70% -44.75% China SXT Pharmaceuticals N/A N/A N/A SummaryBarinthus Biotherapeutics beats China SXT Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.45M$3.08B$5.73B$9.66BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-0.6620.2830.3825.05Price / Sales3.07228.62388.8486.14Price / CashN/A42.3737.0358.50Price / Book0.457.788.976.15Net Income-$61.07M-$54.72M$3.26B$265.47M7 Day Performance-10.65%-0.80%-0.09%-1.51%1 Month Performance-42.13%3.74%3.17%-1.15%1 Year Performance-10.24%7.66%27.76%18.45% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.8558 of 5 stars$1.14+3.4%$3.00+163.2%-10.2%$44.45M$14.97M-0.66107Short Interest ↑Gap UpSXTCChina SXT Pharmaceuticals0.4344 of 5 stars$1.59+0.3%N/A-78.8%$183.90M$1.74M0.0090News CoverageShort Interest ↑DERMJourney Medical1.6939 of 5 stars$8.54+8.5%$9.50+11.2%+58.9%$183.34M$56.13M0.0090Analyst RevisionHigh Trading VolumeTVGNSemper Paratus Acquisition3.9389 of 5 stars$0.96-1.8%$10.00+939.0%+48.9%$180.22MN/A0.003Earnings ReportAnalyst ForecastCYBNCybin2.4598 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$179.99MN/A-1.7450Trending NewsAnalyst RevisionACRSAclaris Therapeutics2.7293 of 5 stars$1.64flat$8.71+431.4%+44.8%$177.66M$18.72M0.00100LFVNLifevantage4.0841 of 5 stars$14.16+2.9%$30.50+115.4%+47.4%$173.21M$200.16M17.87260News CoveragePositive NewsUpcoming EarningsCCCCC4 Therapeutics1.3486 of 5 stars$2.24-7.4%$8.00+257.1%-57.0%$172.23M$35.58M0.00150VYGRVoyager Therapeutics3.5559 of 5 stars$3.39+10.1%$13.25+290.8%-51.8%$170.84M$80M0.00100GLSIGreenwich LifeSciences1.4164 of 5 stars$12.35-1.1%$39.00+215.8%-13.6%$166.97MN/A0.003News CoverageEarnings ReportAnalyst ForecastCTNMContineum Therapeutics3.2985 of 5 stars$6.75+5.0%$22.50+233.3%-49.6%$166.35M$50M0.0031News CoverageAnalyst ForecastShort Interest ↓ Related Companies and Tools Related Companies SXTC Competitors DERM Competitors TVGN Competitors CYBN Competitors ACRS Competitors LFVN Competitors CCCC Competitors VYGR Competitors GLSI Competitors CTNM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access